Back to Agenda
The Responsibility Industry, Agencies, and Early Education own in Cure-Model Based Therapeutics
Session Chair(s)
Dan Tierno, MA, MBA
Associate Director, Project and Portfolio Management
Daiichi Sankyo, Inc, United States
In today’s pharmaceutical and biotech industry we are at an inflection point with regard to the future of therapeutic development. In this forum the focus will be to explore how industry, agencies, and academic institutions collaborate to drive innovative technologies to speed therapeutic development. Specifically, the forum will explore how we are leveraging STEM (Science, Technology, Engineering, Mathematics) programs both independently and interactively to enable current and future entrepreneurial opportunities. The goal is to foster an environment where we best take advantage of the opportunities presented by advances in life sciences and technology.
Learning Objective : Evaluate the quality of interaction among various stakeholders in cure-based drug development; Assess the quality of those interactions in their own environments; Recognize the importance of fostering an environment where creativity and an entrepreneurial spirit is nurtured. Determine how STEM (Science, Technology, Engineering, Mathematics) programs are put to use to address the aforementioned objectives.
Speaker(s)
Industry Perspective
Yaron Drucker, MBA
Google, United States
Staffing Lead, Cloud Partners
Student Perspective
Advaita Chandramohan
University of Southern California, United States
Undergraduate Research Associate
Panelist
Melanie Matheu, PhD
Prellis Biologics, Inc., United States
Founder and Chief Executive Officer
Have an account?